Readystate Asset Management LP Takes $1.51 Million Position in Immunome, Inc. (NASDAQ:IMNM)

Readystate Asset Management LP bought a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 224,240 shares of the company's stock, valued at approximately $1,509,000. Readystate Asset Management LP owned about 0.26% of Immunome at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in shares of Immunome in the fourth quarter worth about $70,000. KLP Kapitalforvaltning AS bought a new stake in shares of Immunome in the fourth quarter worth about $75,000. Tower Research Capital LLC TRC increased its holdings in shares of Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after purchasing an additional 7,129 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Immunome in the fourth quarter worth about $95,000. Finally, Teacher Retirement System of Texas increased its holdings in shares of Immunome by 49.0% in the first quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company's stock worth $117,000 after purchasing an additional 5,712 shares during the last quarter. 44.58% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on IMNM shares. Wedbush reaffirmed an "outperform" rating and issued a $21.00 target price (down from $33.00) on shares of Immunome in a report on Tuesday, May 13th. Lake Street Capital initiated coverage on shares of Immunome in a report on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 price target for the company. Finally, Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $23.33.

Insider Buying and Selling

In other Immunome news, Director Jean Jacques Bienaime bought 5,000 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were purchased at an average price of $9.38 per share, with a total value of $46,900.00. Following the completion of the purchase, the director owned 36,415 shares in the company, valued at $341,572.70. This represents a 15.92% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 8.60% of the company's stock.

Immunome Trading Down 3.3%

NASDAQ:IMNM traded down $0.37 during midday trading on Friday, hitting $10.87. 572,059 shares of the company traded hands, compared to its average volume of 1,181,502. The firm's fifty day moving average is $9.15 and its 200-day moving average is $8.88. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $16.81. The firm has a market capitalization of $945.80 million, a P/E ratio of -3.42 and a beta of 1.92.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.14. The company had revenue of $2.93 million for the quarter, compared to analyst estimates of $0.46 million. Immunome had a negative return on equity of 71.65% and a negative net margin of 1,875.21%. On average, research analysts expect that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.